Gsk (GSK) Non-Current Deferred Tax Liability (2009 - 2026)

Gsk (GSK) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at -$406.5 million in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability rose 20.64% year-over-year to -$406.5 million; the trailing twelve-month figure through Jun 2026 stood at -$406.5 million (up 20.64% YoY), and the FY2025 full-year result was -$387.1 million, up 20.73% from the prior year.
• Non-Current Deferred Tax Liability was -$406.5 million for Q2 2026 at Gsk, down from -$393.7 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of -$187.6 million in Q2 2022 to a low of -$4.7 billion in Q1 2022.
• A 5-year average of -$657.0 million and a median of -$400.1 million in 2026 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability soared 96.26% in 2022 and slumped 233.45% in 2023, its largest moves.
• Gsk's Non-Current Deferred Tax Liability stood at -$339.0 million in 2022, then declined by 13.87% to -$386.0 million in 2023, then retreated by 27.02% to -$490.3 million in 2024, then climbed by 21.05% to -$387.1 million in 2025, then declined by 5.02% to -$406.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were -$406.5 million in Q2 2026, -$393.7 million in Q1 2026, and -$387.1 million in Q4 2025.